Last reviewed · How we verify
SACITUZUMAB GOVITECAN — Competitive Intelligence Brief
marketed
Antibody drug conjugate
Live · refreshed every 30 min
Target snapshot
SACITUZUMAB GOVITECAN (SACITUZUMAB GOVITECAN).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SACITUZUMAB GOVITECAN TARGET | SACITUZUMAB GOVITECAN | marketed | 2020-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SACITUZUMAB GOVITECAN CI watch — RSS
- SACITUZUMAB GOVITECAN CI watch — Atom
- SACITUZUMAB GOVITECAN CI watch — JSON
- SACITUZUMAB GOVITECAN alone — RSS
Cite this brief
Drug Landscape (2026). SACITUZUMAB GOVITECAN — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl3545262. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing